STAT
JUNE 29, 2023
Medical leaders on Thursday reacted swiftly to the Supreme Court’s decision to severely restrict the use of race in college admissions, saying the ruling could reverse decades of progress toward diversifying the nation’s physician workforce — something seen as key to helping end the country’s widespread and deeply entrenched health disparities.
PharmaVoice
JUNE 29, 2023
Transgender and nonbinary patients suffer more adverse health outcomes than the general population, yet are often underrepresented in clinical research. Now, there’s momentum to change the status quo.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
JUNE 29, 2023
Overturning decades of precedent, the U.S. Supreme Court on Thursday struck down the use of affirmative action, ruling that it is unconstitutional for colleges, universities — and professional schools for law, medicine, and nursing — to consider race as one factor in deciding who they will admit. The decision comes as a blow to many in the field of medicine, which has been unable to appreciably increase the numbers of Black, Hispanic, and Indigenous doctors in recent decades.
PharmaVoice
JUNE 29, 2023
From AI to diversity and decentralized trials, here’s how clinical trial operations are evolving.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
STAT
JUNE 29, 2023
The ventilator alarm woke me at 3 a.m. It was the fourth alarm in the past two hours. My 5-year-old daughter Molly had been there eight days, intubated and heavily sedated so she wouldn’t feel her skin blistering off her body, the terrible effect of a severe drug reaction. I looked over and saw her nurse, Kelli, holding Molly’s hand with her right hand and trying to chart with her left.
BioPharma Dive
JUNE 29, 2023
After a prolonged journey, the medicine, known as Roctavian, is now cleared for certain patients with hemophilia A, the more common form of the rare bleeding disorder.
Pharmacist Digest brings together the best content for pharmacists from the widest variety of industry thought leaders.
BioPharma Dive
JUNE 29, 2023
Sigilon Therapeutics, a biotech that’s been collaborating with Lilly since 2018, has agreed to be bought for up to $310 million in the pharma’s second announced buyout this month.
STAT
JUNE 29, 2023
The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder. The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022. Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease.
The Pharmacist
JUNE 29, 2023
Wine drinking is linked to a lower risk of death from cardiovascular disease (CVD) but also reduces the risk of developing both CVD and coronary heart disease (CHD), according to the findings of a recent meta-analysis. Previous studies have hinted that the polyphenolic content of wine confers a cardio-protective effect whereas consumption of spirits, increases the risk of […] The post Wine drinking linked to lower risk of cardiovascular disease appeared first on The Pharmacist.
STAT
JUNE 29, 2023
In 2005, Nick Voyles was diagnosed with hepatitis C after being released from five years of incarceration. A nurse told him he had only six months to live. He was prescribed a drug cocktail, a combination of interferon and ribavirin, that proved ineffective and gave him severe side effects. “It ripped me apart — the entire treatment was killing me,” Voyles, who lives in Bloomington, Ind., recalled.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
European Pharmaceutical Review
JUNE 29, 2023
The US Food and Drug Administration (FDA) has approved Lantidra, the first cell therapy for certain adults with Type 1 diabetes. The allogeneic pancreatic islet therapy is made from deceased donor pancreatic cells and is indicated for Type 1 diabetes patients who are unable to approach target glycated haemoglobin due to current repeated severe hypoglycaemia episodes even with intensive diabetes management and education.
STAT
JUNE 29, 2023
The owner of a pharmaceutical wholesaler has been indicted for his alleged role in distributing misbranded HIV pills, a sign that U.S. authorities are now targeting an extensive scheme that pumped the medicines into the pharmaceutical supply chain. Steven Diamantstein, who runs Scripts Wholesale in Brooklyn, N.Y., was indicted for participating in a conspiracy in which at least $150 million worth of HIV medicines were purchased at “steeply discounted” prices from patients and then
Pharma Times
JUNE 29, 2023
Partnership establishes several influenza therapy targets using artificial intelligence - News - PharmaTimes
STAT
JUNE 29, 2023
Alkermes shareholders voted Thursday to re-elect all of the drugmaker’s current directors, ending an acrimonious proxy fight with hedge fund Sarissa Capital Management, which had sought to seat three directors on the board. At the company’s annual meeting, shareholders voted in favor of Alkermes’ proposal to retain all seven of the director nominees to the 11-person board.
Orsini Pharmacy
JUNE 29, 2023
The complexities of managing the care of a rare disease patient are tremendous. Several models of care are efficient when optimizing patient care services with rare disease limited distribution drugs; however, the most promising is the concierge model. This model is where all communications would filter through the health plan. The health plan has a line of sight to precisely what that patient needs and where to get their drug.
STAT
JUNE 29, 2023
Can Novavax finally get it right? What’s a “triple-G” drug? And is Novo Nordisk losing ground? We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. Our colleague Elaine Chen joins us to explain how the era of Wegovy could be short-lived in light of powerful new weight-loss medicines from Eli Lilly.
The Pharmacist
JUNE 29, 2023
Lisa Olins, pharmacist manager at Crown Pharmacy in Shenley, Hertfordshire, talks to Saša Janković about a tie-up between ambulatory blood pressure monitoring (ABPM) and NMS services Service type: Ambulatory blood pressure monitoring and New Medicine Service Name and location of pharmacy: Crown Pharmacy, Shenley Name of pharmacist: Lisa Olins Why did you start offering this service?
STAT
JUNE 29, 2023
Top of the morning to you. A delicious cool breeze and shiny sun are hovering over the Pharmalot campus, where birds are singing, mascots are barking, and another cup of stimulation is brewing (our choice today is roasted coconut). A fine start to the day, yes? Hopefully, things will continue on this trajectory, despite the smoky skies heading our way from Canada.
Express Pharma
JUNE 29, 2023
The acquisition of the Myoril brand for the Indian market is effective from June 28, 2023 CORONA Remedies has announced the acquisition of the Myoril brand from the global pharma giant Sanofi. The acquisition, valued at Rs 234 crore (including taxes), marks CORONA’s largest acquisition to date. With the Myoril brand becoming a part of its portfolio, CORONA gains its first offering in the muscle relaxant category, strengthening its existing lineup of more than 80 brands.
The Pharmacist
JUNE 29, 2023
A company which provides online health testing kits has partnered with Superdrug under a two-year deal to help people ‘make informed decisions about their health and lifestyle’. Thriva will be offering its health tests through the high-street pharmacy chain for heart disease and diabetes risk, liver function, fertility, white blood cell count, vitamin D levels, iron […] The post Superdrug deal for Thriva at-home and in-store testing appeared first on The Pharmacist.
European Pharmaceutical Review
JUNE 29, 2023
New drug mirikizumab doubled remission rates up to 50 percent in certain patient groups in two ulcerative colitis (UC) Phase III trials. Results from the studies were recently published in the New England Journal of Medicine. Researchers identified Interleukin-23 as an important protein in triggering and maintaining gut inflammation. This is relevant in Crohn’s disease, ulcerative colitis and chronic skin disease psoriasis.
Pharmaceutical Technology
JUNE 29, 2023
Genprex has announced that the FDA has granted fast-track designation for Reqorsa, its small cell lung cancer (SCLC) therapy.
European Pharmaceutical Review
JUNE 29, 2023
Based on scientific knowledge and process understanding, manufacturers of drugs and drug substances have a broad awareness of potential impurities – including nitrosamine impurities – that could form during manufacturing or degradation. However, it is difficult to predict exactly how processes could behave and how materials could react under each process conditions.
BioPharma Dive
JUNE 29, 2023
The yet-to-be-announced deal for the German biotech is the latest move by Lilly to bulk up its oncology business, adding a drug in early development for solid tumors.
Pharmaceutical Technology
JUNE 29, 2023
The FDA has announced that Lantidra, a cellular therapy for type 1 diabetes, has become the first treatment of its kind to be approved.
Outsourcing Pharma
JUNE 29, 2023
Anebulo Pharmaceuticals is currently developing a new, first-of-its-kind drug, ANEB-001, intended to rapidly reverse the negative effects of ACI within one hour of administration. The treatment is a cannabinoid receptor antagonist, which blocks THC, the substance which gives cannabis its psychotropic effects, from binding in a personâs CB1 receptor.
Pharmaceutical Technology
JUNE 29, 2023
Carrie Harney, the vice president of government and regulatory Affairs at US Pharmacopeia (USP) explains US drug shortages.
Express Pharma
JUNE 29, 2023
Manufactured using Enzene Biosciences’ patented Continuous Manufacturing Process, Bevacizumab is a biosimilar to Avastin and will be available through a non-exclusive partnership for pharmaceutical firms in India Pune-based Enzene Biosciences has now announced the India launch of Bevacizumab, a biosimilar of Avastin that is used for the treatment of metastatic colorectal cancer.
Pharmaceutical Technology
JUNE 29, 2023
Experts warn caution around CRISPR gene editing technology on human embryos as it may have dangerous consequences.
Outsourcing Pharma
JUNE 29, 2023
uMotif is starting to reap the rewards of its patient first technology â that really does what it says on the tin, says the companyâs CEO, Steve Rosenberg.
Pharma Times
JUNE 29, 2023
PrecisionLife to analyse OXEGENE data to improve mechanistic understanding of endometriosis - News - PharmaTimes
pharmaphorum
JUNE 29, 2023
FDA approves first cell therapy for type 1 diabetes Phil.
The Pharmacist
JUNE 29, 2023
Pharmacy multiple Boots has announced the closure of 300 UK stores over the next twelve months, citing the need to concentrate its team members ‘where they are needed’. Community Pharmacy England chief executive Janet Morrison said that the move was ‘not surprising’ and reflective of the pressures currently experienced by community pharmacy. The pharmacy chain […] The post Boots closures will ‘consolidate’ stores and workforce appeared first on The Pharmacist.
pharmaphorum
JUNE 29, 2023
England turns to digital health checks to cut GP pressure Phil.
BioPharma Dive
JUNE 29, 2023
The latest regulatory setback, tied to continuing manufacturing issues, ensures Alvotech and partner Teva won’t be able to launch their drug alongside a wave of emerging Humira copycats.
Expert insights. Personalized for you.
316 
Let's personalize your content